Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension (Q48533276)

12 February 2018

title

Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension (English)

1 reference

12 February 2018

author name string

Peter Norman

series ordinal

1

1 reference

12 February 2018

language of work or name

English

0 references

publication date

26 January 2015

1 reference

12 February 2018

Expert Opinion on Therapeutic Patents

published in

1 reference

12 February 2018

volume

25

1 reference

12 February 2018

issue

4

1 reference

12 February 2018

page(s)

493-499

1 reference

12 February 2018

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States

cites work

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

An epidemiological study of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

The pharmacological treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Implication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Reversible or irreversible remodeling in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Targeting PDGF pathway in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

PDGF signaling in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Crenolanib is a selective type I pan-FLT3 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2015.1007042

10.1517/13543776.2015.1007042

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018